Relapsed and Refractory Multiple Myeloma Clinical Trial
Official title:
Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma (SELVEDge Study)
The purpose of this research is to determine whether the combination of selinexor, venetoclax, and dexamethasone therapy can increase anti-cancer effects in patients with translocation 11;14-positive (t(11;14)), relapsed/refractory myeloma (RRMM).
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06050512 -
Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma
|
Phase 1/Phase 2 | |
| Completed |
NCT00932698 -
Study of Oral Ixazomib in Adult Participants With Relapsed and/or Refractory (RR) Multiple Myeloma
|
Phase 1 | |
| Terminated |
NCT03683277 -
IPD in RRMM Characterized With Genomic Abnormalities of Adverse Prognostic
|
Phase 2 | |
| Recruiting |
NCT04155749 -
Master Protocol for the Phase 1 Study of Cell Therapies in Multiple Myeloma
|
Phase 1 | |
| Completed |
NCT03029234 -
Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma
|
Phase 3 | |
| Not yet recruiting |
NCT03559764 -
Study of BCMA CAR-T in Multiple Myeloma
|
Early Phase 1 | |
| Completed |
NCT02144038 -
Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple Myeloma
|
Phase 1 | |
| Terminated |
NCT00664378 -
Efficacy Study of CYT997 in Multiple Myeloma
|
Phase 2 | |
| Terminated |
NCT03710915 -
A Study of HG146 Capsule in Chinese Subjects With Relapsed and Refractory Multiple Myeloma
|
Phase 1 | |
| Terminated |
NCT02223598 -
A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological Malignancies
|
Phase 1 | |
| Completed |
NCT03477643 -
Retrospective Viability Study of the PETHEMA-POMCIDEX Clinical Practice Guidelines for the Treatment of Patients With Relapsed and Refractory Multiple Myeloma (RRMM)
|
||
| Recruiting |
NCT03661554 -
BCMA Nano Antibody CAR-T Cells for Patients With Refractory and Relapsed Multiple Myeloma
|
Early Phase 1 |